Transvaginal placement of surgicalmesh for pelvic organ prolapse has the potential to improve quality of life and anatomic outcomes (especially in the anterior compartment), but also has potential serious adverse events as outlined by the FDA’s July 2011 Safety Communication (http://www.fda.gov/medicaldevices/safety/alertsandnotices/ucm262435.htm). This document provides Guidelines for privileging and credentialing of physicians planning to implement or continue using this new technology in clinical practice.
Reprints: Operations Manager, American Urogynecologic Society, 2025 M Street, NW Suite 800, Washington, DC 20036. E-mail: email@example.com.
The authors declare that they have nothing to disclose.
This document was developed by the American Urogynecologic Society’s Guidelines Development Committee and approved by its Board of Directors.
Disclaimer: This document reflects emerging clinical and scientific advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed, or as dictating the standard of care for credentialing of surgeons. The ultimate judgment regarding any specific procedure or treatment is to be made by the physician and patient in light of all circumstances presented by the patient. The selection of specific credentialing criteria is to be made by the institution in consultation with medical leadership. This document is not expected to reflect the opinions of all members of the American Urogynecologic Society.